FDAsafety guidance83% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Roche.
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Oncology · KRAS Inhibitor
- Sub-indication
- General
Related signal: Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation